Calibration Technician
About the job
- Applicants should have an Associate of Applied Science degree, preferably in an Engineering or Construction Technologies related area.
- Calibration Technician II requires 2 or more years of related experience, or a high school diploma or GED with 5 or more years of related experience.
- Calibration Technician III requires 5 or more years of related experience, or a high school diploma or GED with 8 or more years of related experience.
- Calibration Technician IV requires 8 or more years of related experience, or a high school diploma or GED with 8 or more years of related experience.
- Must be willing and able to work Sunday through Thursday, 10:00 p.m. to 8:30 a.m.
- Must be able to lift, push, and pull at least 50 pounds.
- Must have knowledge of Microsoft Office Suite and general familiarity with computer systems.
- Must be able to work in full gowning when entering and working on the production floor.
- Must participate in a rotating on-call schedule.
- Calibrate instruments including temperature, pressure, level, flow, and analytical instruments.
- Perform instrumentation loop checks, tuning, troubleshooting, and start-up.
- Work with medium and low voltages.
- Perform basic plumbing and tube-bending jobs.
- Assist Facilities Management-Maintenance process and Clean Utility technicians with troubleshooting facility- and process-related issues.
- Perform daily work orders and preventive maintenance, and coordinate the workflow and documentation of preventive maintenance and work orders.
- Communicate and coordinate with departments and Facilities Management when planned and unplanned work events occur.
- Follow current Good Manufacturing Practices.
- Perform other facility-related tasks and address issues outside the calibration department's normal duties as needed.
- Plan and schedule outside contractors or vendors for scheduled or unscheduled preventive maintenance or general work as needed.
- Maintain plant manufacturing equipment and related support equipment safely and efficiently, adhering to standard operating procedures, Good Manufacturing Practices, and quality standards.
- Participate in compliance investigations as needed.
- Prior experience in the maintenance and operation of a large-scale utilities plant is preferred.
- ISA Certified Control Systems Technician certification is strongly preferred but not required.
About the company
Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.
Company Size
10,001+
Company Stage
IPO
Headquarters
Town of Mount Pleasant, New York
Founded
1988
Get referred to Regeneron Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Sanofi paid $1 billion upfront, with up to $7 billion more for Regeneron's immunology pipeline.
- Q2 2026 revenue rose 17% to $4.3 billion; Dupixent sales hit $6.0 billion.
- Libtayo and EYLEA HD both posted record sales in Q2 2026, widening diversification.
What critics are saying
- EYLEA biosimilar competition starts in January 2027 after Samsung's settlement.
- Regeneron faces a 2026 SDNY securities class action over the failed fianlimab melanoma trial.
- Dupixent's patent cliff later this decade threatens the company's biggest profit pool.
What makes Regeneron Pharmaceuticals unique
- VelocImmune keeps generating partnered immunology assets; Sanofi renewed the alliance on October 1, 2026.
- Dupixent remains Regeneron's engine, with over 1.5 million patients across nine indications.
- EYLEA HD conversion shows platform strength; U.S. sales hit $596 million in Q2 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Wellness Program
Paid Vacation
Equity Awards
Annual Bonuses
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 10%1 year growth
↑ 12%2 year growth
↑ 12%France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.
Regeneron and Sanofi expand collaboration to develop long-acting immunology antibodies. Thursday, October 01, 2026 Regeneron Pharmaceuticals and Sanofi have expanded their long-standing antibody collaboration to develop and commercialise a new group of long-acting immunology treatments. Dupixent is a fully human monoclonal antibody that blocks signalling through the IL-4 and IL-13 pathways. It was developed using Regeneron's VelocImmune technology and is not an immunosuppressant. The agreement builds on more than two decades of work between the companies and their development of Dupixent (dupilumab), a widely used treatment for diseases linked to type 2 inflammation. Under the expanded agreement, the companies will jointly develop and commercialise four long-acting antibodies discovered by Regeneron. The candidates target interleukin-13 (IL-13), IL-4 and IL-4 pathways, including an IL-4xIL-13 bispecific antibody and an antibody targeting the IL-4 receptor alpha (IL-4Rα). REGN20423, an IL-13 antibody, is currently being evaluated in a Phase 1 clinical trial for atopic dermatitis. The other three antibody programmes are expected to enter clinical studies in 2027. Regeneron will also have the option to add Sanofi's investigational lunsekimig to the collaboration after completion of its Phase 3 trials in chronic obstructive pulmonary disease. Lunsekimig is a bispecific Nanobody therapy designed to target thymic stromal lymphopoietin (TSLP) and IL-13. As part of the agreement, Sanofi will pay Regeneron $1 billion upfront. Regeneron could receive up to a further $7 billion through development, regulatory and commercial milestones. The companies will share development and commercialisation costs for the new programmes and divide future profits equally worldwide. Regeneron will lead research and development activities, while Sanofi will oversee global commercialisation. The existing profit-sharing arrangement for Dupixent will remain unchanged. The companies have also resolved their previous litigation related to their collaboration. The expanded alliance continues a partnership that began in 2003. The collaboration has resulted in several approved medicines, with Dupixent becoming a major treatment for conditions associated with type 2 inflammation. More than 1.5 million people are currently receiving Dupixent worldwide. The medicine has been approved in more than 60 countries for a range of conditions, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease, bullous pemphigoid and allergic fungal rhinosinusitis, across different age groups. Regeneron and Sanofi are also evaluating dupilumab in additional conditions associated with type 2 inflammation and allergic processes. These include chronic pruritus of unknown origin. These potential uses remain under clinical investigation and have not yet been fully evaluated for safety and efficacy by regulatory authorities.
Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute. By Thomson Reuters Oct 1, 2026 | 1:16 AM By Bhanvi Satija and Mariam Sunny Oct 1 (Reuters) - Sanofi and Regeneron said on Thursday they will develop four new drugs together in a deal worth up to $8 billion and settle prior litigation, moves analysts said signal a reset of their strained partnership and an early win for the French drugmaker's new CEO Belen Garijo. Sanofi will pay $1 billion upfront with an additional $7 billion in potential milestone payments. The companies will equally share development costs and future profits on the four drugs, with Regeneron leading research and Sanofi handling global sales if they are approved. Sanofi shares closed up nearly 1% on Thursday. Shares of Tarrytown, New York-based Regeneron were down 4% in midday trading. "Mutual trust will be the guiding principle in this extended relationship," Garijo said on an investor call, adding that the partnership would include clear roles and accountability for both firms. Garijo, who took over the top role at Sanofi in May and is leading a strategic review of the company, has promised investors faster decision-making. Barclays analysts noted that her predecessor, Paul Hudson, had tried and failed to expand the Regeneron alliance, which produced Sanofi's top-selling medicine, Dupixent, among other drugs. "While the assets are early-stage, the expansion should be viewed positively, as it signals the new CEO's proactive focus on the most important yet addressable uncertainties investors face," said Jefferies analyst Michael Leuchten. The four antibody drugs target the same type 2 inflammation pathways as Dupixent and include REGN20423, currently in early-stage testing for atopic dermatitis, an intensely itchy skin condition also known as eczema. The other three are expected to begin clinical testing in 2027. Regeneron will become eligible for the first $1 billion milestone payment when REGN20423 enters late-stage testing, the drugmaker said. Garijo said the atopic dermatitis market could double in the next five years. "We believe today's deal marks an important step in repairing their relationship and removes a key overhang for both," said BMO Capital Markets analyst Evan Seigerman. However, Markus Manns, a portfolio manager at Union Investment, which holds Sanofi shares, questioned the cost, given the uncertainties of such early-stage assets. "Sanofi certainly paid a full price," he said. MORE M&A REQUIRED Analysts broadly viewed the deal positively but some warned it does not solve Sanofi's fundamental challenge of finding enough pipeline strength to offset Dupixent's patent loss later this decade. Dupixent accounted for 36% of Sanofi's nearly 44 billion euros ($49.39 billion) in 2025 sales. It is approved to treat several conditions, including eczema, asthma, nasal polyps and chronic obstructive pulmonary disease. Sanofi said it was actively working to extend Dupixent's patent exclusivity, but declined to provide details. "This (deal) is the necessary first step toward Sanofi regaining investor trust, but a great deal more is required given a decade of R&D challenges," Guggenheim analysts said. ($1 = 0.8909 euros) (Reporting by Hugo Lhomedet and Matthieu Huchet in Gdansk, Bhanvi Satija in London, and Mariam Sunny in Bengaluru, editing by Milla Nissi-Prussak, Louise Heavens and Bill Berkrot)
Sanofi and Regeneron expand global alliance. 1 October 2026 French pharma major Sanofi (Euronext: SAN) and USA-based Regeneron Pharmaceuticals (Nasdaq: REGN) today announce an expansion of their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to the alliance that has jointly established Dupixent (dupilumab) as the world-leading treatment for diseases driven by type 2 inflammation. The agreement builds on the companies' more than 20-year collaboration, through which more than 1.5 million people are currently receiving Dupixent across nine indications, making it one of the most widely used antibody medicines in the world. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 24 July 2026 30 July 2026 18 August 2026 Company news directory. Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 1 October 2026 Company spotlight. A Boston biotech whose antibody-drug conjugate micvotabart pelidotin targets the tumor's structural scaffold rather than its cells, now funded toward a Phase 3 trial in recurrent head and neck cancer. More features in biotechnology. 1 October 2026 30 September 2026
Regeneron Pharmaceuticals' stock has declined roughly 1% this year, despite being a strong long-term performer. The biotech company will report third-quarter earnings on 30 October, which could provide a catalyst for the struggling share price. When Regeneron last reported results in July, revenue totalled $4.3 billion, up 17% year-over-year. Global sales of Dupixent and Libtayo rose 38% and 30% respectively, whilst Eylea HD revenue in the US climbed 52%. The strong figures pushed the stock to a new 52-week high in early September. The company has roughly 50 product candidates in development. Regeneron trades at 19 times trailing earnings and less than 15 times forward earnings, compared to the S&P 500's multiples of 23 and 20 respectively.